Advances in tuberculosis in 2019 in Canada and globally

References

• Essien S, Epp T, Waldner C, Wobeser W, Hoeppner V. Tuberculosis in Canada and the United States: a review of trends from 1953 to 2015. Can J Public Health. 2019;110(6):697–704. doi:10.17269/s41997-019-00236-x.
   Web of Science ®Google Scholar
• Long R, Heffernan C, Cardinal-Grant M, et al. Two row wampum, human rights, and the elimination of tuberculosis from high-incidence indigenous communities. Health Hum Rights. 2019;21(1): 253–265.
   PubMed Web of Science ®Google Scholar
• Kilabuk E, Momoli F, Mallick R, et al. Social determinants of health among residential areas with a high tuberculosis incidence in a remote Inuit community. J Epidemiol Commun Hlth. 2019;73(5): 401–406.
   Web of Science ®Google Scholar
• Houben R, Dodd P. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLOS Med. 2016;13(10):e1002152. doi:10.1371/journal.pmed.1002152.
   PubMed Web of Science ®Google Scholar
• Yasseen A, Rea E, Hirji M, et al. Paediatric tuberculosis among the foreign-born: utility of the Canadian TB immigration medical surveillance programme. Int J Tuber Lung Dis. 2019;23(1): 105–111.
   Web of Science ®Google Scholar
• Long R, Asadi L, Heffernan C, et al. Is there a fundamental flaw in Canada’s post-arrival immigrant surveillance system for tuberculosis?. PLoS One. 2019;14(3):e0212706. doi:10.1371/journal.pone.0212706.
   PubMed Web of Science ®Google Scholar
• Tait D, Hatherill M, Van Der Meeren O, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Eng J Med. 2019;381(25): 2429–2439.
   PubMed Web of Science ®Google Scholar
• Khader S, Divangahi M, Hanekom W, et al. Targeting innate immunity for tuberculosis vaccination. The Journal of Clinical Investigation. 2019;129(9):3482–3491. doi:10.1172/JCI128877.
   Web of Science ®Google Scholar
• Khan N, Mendonca L, Dhariwal A, et al. Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis. Mucosal Immunol. 2019;12(3):772–783. doi:10.1038/s41385-019-0147-3.
   PubMed Web of Science ®Google Scholar
• Sterling T, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC, 2020. MMWR. 2020.
   Google Scholar
• WHO. Latent Tuberculosis Infection: updated and Consolidated Guidelines for Programmatic Management. Geneva, Switzerland: WHO; 2018.
   Google Scholar
• Foreman T, Bucşan A, Mehra S, et al. Isoniazid and Rifapentine treatment eradicates persistent Mycobacterium tuberculosis in Macaques. AM J Resp Crit Care Med. 2019. doi: 10.1164/rccm.201903-0646OC. [Epub ahead of print]
   Google Scholar
• Sterling TR, Villarino ME, Borisov AS, et al. Three months of Rifapentine and Isoniazid for latent tuberculosis infection. New Engl J Med. 2011;365(23): 2155–2166.
   PubMed Web of Science ®Google Scholar
• Sterling T, Moro R, Borisov A, et al. Flu-like and other systemic drug reactions among persons receiving weekly Rifapentine Plus Isoniazid or daily Isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study. Clin Infect Dis. 2015;61(4):527–535. doi:10.1093/cid/civ323.
   PubMed Web of Science ®Google Scholar
• Diallo T, Adjobimey M, Ruslami R, et al. Safety and side effects of Rifampin versus Isoniazid in children. N Eng J Med. 2018;379(5): 454–463.
   PubMed Web of Science ®Google Scholar
• Menzies D, Adjobimey M, Ruslami R, et al. Four months of Rifampin or nine months of Isoniazid for latent tuberculosis in adults. N Eng J Med. 2018;379(5): 440–453.
   PubMed Web of Science ®Google Scholar
• Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of Rifampin Therapy or 9 months of Isoniazid Therapy for latent tuberculosis infection. Annals Int Med. 2008;149(10): 689–697.
   PubMed Web of Science ®Google Scholar
• Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with Rifampin vs Isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166(17):1863–1870. doi:10.1001/archinte.166.17.1863.
   PubMedGoogle Scholar
• Ena J, Valls V. Short-Course therapy with Rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005;40(5): 670–676.
   PubMed Web of Science ®Google Scholar
• Gupta A, Montepiedra G, Aaron L, et al. Isoniazid preventive therapy in HIV-infected pregnant and postpartum Women. N Eng J Med. 2019;381(14): 1333–1346.
   PubMed Web of Science ®Google Scholar
• Swindells S, Ramchandani R, Gupta A, et al. One month of Rifapentine plus Isoniazid to prevent HIV-related tuberculosis. N Eng J Med. 2019;380(11): 1001–1011.
   PubMed Web of Science ®Google Scholar
• Romanowski K, Baumann B, Basham C, Ahmad Khan F, Fox G, Johnston J. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19(10): 1129–1137.
   Web of Science ®Google Scholar
• Ronald L, Campbell J, Rose C, et al. Estimated impact of World Health Organization latent tuberculosis screening guidelines in a region with a low tuberculosis incidence: retrospective cohort study. Clin Infect Dis. 2019;69(12): 2101–2108.
   Web of Science ®Google Scholar
• Alsdurf H, Hill P, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11): 1269–1278.
   PubMed Web of Science ®Google Scholar
• Pease C, Zwerling A, Mallick R, et al. The latent tuberculosis infection cascade of care in Iqaluit, Nunavut, 2012–2016. BMC Infect Dis. 2019;19(1): 890. doi:10.1186/s12879-019-4557-3.
   Web of Science ®Google Scholar
• Marks G, Nguyen N, Nguyen P, et al. Community-wide screening for tuberculosis in a high-prevalence setting. N Eng J Med. 2019;381(14): 1347–1357.
   Web of Science ®Google Scholar
• Merle C, Fielding K, Sow OB, et al. A four-month Gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588–1598. doi:10.1056/NEJMoa1315817.
   PubMed Web of Science ®Google Scholar
• Gillespie SH, Crook A, McHugh T, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–1587. doi:10.1056/NEJMoa1407426.
   PubMed Web of Science ®Google Scholar
• Jindani A, Harrison TS, Nunn AJ, et al. High-dose Rifapentine with Moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599–1608. doi:10.1056/NEJMoa1314210.
   PubMed Web of Science ®Google Scholar
• Nafade V, Huddart S, Sulis G, et al. Over-the-counter antibiotic dispensing by pharmacies: a standardised patient study in Udupi district, India. BMJ Glob Health. 2019;4(6):e001869. doi:10.1136/bmjgh-2019-001869.
   PubMed Web of Science ®Google Scholar
• Satyanarayana S, Kwan A, Daniels B, et al. Use of standardised patients to assess antibiotic dispensing for tuberculosis by pharmacies in urban India: a cross-sectional study. Lancet Infect Dis. 2016;16(11): 1261–1268.
   PubMed Web of Science ®Google Scholar
• WHO. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Switzerland: World Health Organization; 2019.
   Google Scholar
• Ahmad N, Ahuja S, Akkerman O, Alffenaar J, Anderson L, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150): 821–834.
   PubMed Web of Science ®Google Scholar
• Lan Z, Ahmad N, Baghaei P, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020. doi:10.1016/S2213-2600(20)30047-3
   Google Scholar
• von Groote-Bidlingmaier F, Patientia R, Sanchez E, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019;7(3): 249–259.
   PubMed Web of Science ®Google Scholar